Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Fevipiprant 150 mg	32
Overall Study	STARTED	Fevipiprant 450 mg	34
Overall Study	STARTED	Placebo	32
Overall Study	Full Analysis Set (FAS)	Fevipiprant 150 mg	31
Overall Study	Full Analysis Set (FAS)	Fevipiprant 450 mg	32
Overall Study	Full Analysis Set (FAS)	Placebo	28
Overall Study	Safety Analysis Set (SAF)	Fevipiprant 150 mg	32
Overall Study	Safety Analysis Set (SAF)	Fevipiprant 450 mg	34
Overall Study	Safety Analysis Set (SAF)	Placebo	32
Overall Study	COMPLETED	Fevipiprant 150 mg	32
Overall Study	COMPLETED	Fevipiprant 450 mg	32
Overall Study	COMPLETED	Placebo	31
Overall Study	NOT COMPLETED	Fevipiprant 150 mg	0
Overall Study	NOT COMPLETED	Fevipiprant 450 mg	2
Overall Study	NOT COMPLETED	Placebo	1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03681093/flow